UroToday reports results of second Australian Lutetium-177 PSMA-617 trial

[Admin]

Some of our members are participating in the third Australian Lutetium-177 trial. In this current trial, Lutetium-177 is being compared with the best current treatment - Cabazitaxel (Jevtana).

Lutetium-177 is also known as Lu-177 or 177Lu or Lutetium-177 PSMA-617.
We earlier reported on the results of the first Australian Lutetium-177 trial:

 

Now UroToday has reported the results of the second trial here:

https://t.co/LpQf8G0hdT 

OR

https://www.urotoday.com/conference-highlights/asco-gu-2019/asco-gu-2019-prostate-cancer/110311-asco-gu-2019-results-of-a-50-patient-single-centre-phase-ii-prospective-trial-of-lutetium-177-psma-617-theranostics-in-mcrpc.html?utm_source=newsletter_6299&utm_medium=email&utm_campaign=emerging-data-in-the-treatment-of-men-with-mcrpc

If you are further interested, Michael Hofman, who led the study from the Peter MacCallum Centre in Melbourne, Australia is interviewed here:

https://www.urotoday.com/video-lectures/asco-gu-2019/video/mediaitem/1155-embedded-media2019-02-23-19-51-36.html

The first time you go to UroToday you will need to sign up, but signing up is free.
If these links do not work for you, on the UroToday.com site, search for: hofman

Thanks to member Chuck for the referral to this report.

Jim